Prenoxdiazine (marketed as Libexin) is a cough suppressant.[1] It acts peripherally by desensitizing the pulmonary stretch receptors. Therefore, there's a reduction of cough impulses originating in the lungs. Prenoxdiazine is indicated in cough of bronchial origin.

Prenoxdiazine
Clinical data
Trade namesLibexin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 1-[2-[3-(2,2-diphenylethyl)-1,2,4-oxadiazol-5-yl]ethyl]piperidine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H27N3O
Molar mass361.489 g·mol−1
3D model (JSmol)
  • n1c(onc1CC(c2ccccc2)c3ccccc3)CCN4CCCCC4
  • InChI=1S/C23H27N3O/c1-4-10-19(11-5-1)21(20-12-6-2-7-13-20)18-22-24-23(27-25-22)14-17-26-15-8-3-9-16-26/h1-2,4-7,10-13,21H,3,8-9,14-18H2 checkY
  • Key:PXZDWASDNFWKSD-UHFFFAOYSA-N checkY
  (verify)

References

edit
  1. ^ Csürös L (1989). "Fifteen years of experience on the use of Libexin tablets". Therapia Hungarica. 37 (1): 50–4. PMID 2667194.